Biotech startup Vella Bioscience launches scientific research consortium for study of women's sexual wellness

Vella Bioscience, a biotech startup in service of female sexual empowerment, has announced a Consortium for the Study of Women's Sexual Wellness. The new initiative brings together ten renowned experts with a shared mission of advancing innovation in non-pharmaceutical female sexual health tools.

Sexual arousal, uterine pain, and the vaginal microbiome are some of the initial topics of its research. By providing educational resources and basic science and clinical protocols that are necessary to clearly profile product efficacy and safety for female consumers, the Consortium aims to advance scientific rigor for women's sexual health and deepen the public's knowledge of female bodies. The Mission of the Consortium is to:

• Support research, education, and public awareness of female sexual health and wellness.
• Bring scientific rigor to the basic science and clinical science research of sexual wellness products, including the utilization of double-blind, placebo-controlled, randomized clinical trials and the development of an advanced protocol for microbiome safety screening.
• Enable healthcare providers and customers to directly access research protocols and validated products for the management of sexual wellness.
• Establish a public-facing community of like-minded providers who support women in their sexual journey and difficulties.

The consortium's mission will be driven by a Scientific Advisory Board (SAB), comprised of internationally recognized experts in female sexual health and medicine. 

Carolyn Wheeler, CEO and Co-founder, Vella Bioscience: "Research and innovation in women's health is grossly underserved. Solutions to help us live equally full lives are underdeveloped or nonexistent. The formation of the Consortium is about establishing new norms for women by increasing public education and offering guidance for best practices for evaluating efficacy. We invite our colleagues in this field to join us on this mission. We need all hands on deck. There's way too much to do and we need to do it as quickly as possible to make up for so much lost time."

The Consortium looks forward to announcing more details on its research activities, resource library, and opportunities for clinical study participation.

www.vellabio.com